Amongst sufferers domestically superior, unresectable, stage 3 non-small cell lengthy most cancers (NSCLC) that has not progressed after platinum-based concurrent chemoradiation (cCRT),...
Sufferers with beforehand handled, regionally superior or metastatic hormone receptor (HR)-positive, HER2-negative breast most cancers skilled superior progression-free survival when handled with...
Amongst sufferers with high-risk, HER2-positive early breast most cancers, presurgical, or neoadjuvant, remedy with Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) adopted by paclitaxel, Herceptin...
Amongst sufferers with high-risk cutaneous squamous cell carcinoma (CSCC), postsurgical therapy with Libtayo (cemiplimab-rwlc) has been discovered to be related to an...
